Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review

Cancer Treatment Reviews

Volumn 38, Issue 5, 2012, Pages 505-514

  Baas, J M ^a   Krens, L L ^a   Guchelaar, H J ^a   Ouwerkerk, J ^a   Jong, F A de ^b   Lavrijsen, A P M ^a   Gelderblom, H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Amgen BV Dept of Medical Oncology en Hematology   (Netherlands)

Author keywords

EGFR inhibitors; Guideline; Prophylaxis; Skin toxicity

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; HYDROCORTISONE; IRINOTECAN; LAPATINIB; LETROZOLE; MINOCYCLINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PIMECROLIMUS; PLATINUM; TAXANE DERIVATIVE; TAZAROTENE; TETRACYCLINE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; DRUG EFFICACY; EPIDERMIS CELL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KERATINOCYTE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; PANCREAS CANCER; PATHOPHYSIOLOGY; PREDICTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN TOXICITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; SKIN DISEASES; TREATMENT OUTCOME;

EID: 84861199721     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.09.004     Document Type: Review

References (80)

1. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578.
2. Burtness B., Goldwasser M.A., Flood W., Mattar B., Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative oncology group study. J Clin Oncol 2005, 23(34):8646-8654.
3. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357(20):2040-2048.
4. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373(9674):1525-1531.
5. Sobrero A.F., Maurel J., Fehrenbacher L., et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(14):2311-2319.
6. van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007, 25(13):1658-1664.
7. van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360(14):1408-1417.
8. Galimont-Collen A.F., Vos L.E., Lavrijsen A.P., Ouwerkerk J., Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007, 43(5):845-851.
9. Perez-Soler R., Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 2005, 23(22):5235-5246.
10. Segaert S., van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005, 16(9):1425-1433.
11. Di Leo A., Gomez H.L., Aziz Z., et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008, 26(34):5544-5552.
12. Lacouture M.E., Laabs S.M., Koehler M., et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2009, 114(3):485-493.
13. Wagner L., Lai S.E., Aneja M., et al. Development of a functional assessment of side-effects to therapy (FAST) questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors (EGFRI): The FAST-EGFRI. J Clin Oncol 2007, 25(18s). Abstr. 19532.
14. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19(13):3267-3279.
15. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290(16):2149-2158.
16. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002, 20(9):2240-2250.
17. Nanney L.B., Stoscheck C.M., King L.E., Underwood R.A., Holbrook K.A. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990, 94(6):742-748.
18. Jost M., Kari C., Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000, 10(7):505-510.
19. Lacouture M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006, 6(10):803-812.
20. Busam K.J., Capodieci P., Motzer R., Kiehn T., Phelan D., Halpern A.C. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001, 144(6):1169-1176.
21. Malik S.N., Siu L.L., Rowinsky E.K., et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003, 9(7):2478-2486.
22. DeWitt C.A., Siroy A.E., Stone S.P. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 2007, 56(3):500-505.
23. van Doorn R., Kirtschig G., Scheffer E., Stoof T.J., Giaccone G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002, 147(3):598-601.
24. Albanell J., Rojo F., Averbuch S., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002, 20(1):110-124.
25. Amitay-Laish I., David M., Stemmer S.M. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. Oncologist 2010, 15(9):1002-1008.
26. Woodworth C.D., Michael E., Marker D., Allen S., Smith L., Nees M. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 2005, 4(4):650-658.
27. Lu P.H., Kuo T.C., Chang K.C., Chang C.H., Chu C.Y. Gefitinib-induced epidermal growth factor receptor (EGFR)-independent keratinocyte apoptosis is mediated by the JNK-activation pathway. Br J Dermatol 2010, 164(1):38-46.
28. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004, 22(1):77-85.
29. Cohen E.E., Rosen F., Stadler W.M., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003, 21(10):1980-1987.
30. Perez-Soler R., Chachoua A., Hammond L.A., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004, 22(16):3238-3247.
31. Mohamed M.K., Ramalingam S., Lin Y., et al. Skin rash and good performance status (PS) predict impoved survival with gefitinib for patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004, 22(14s). Abstr. 7097.
32. Jatoi A., Green E.M., Rowland K.M., Sargent D.J., Alberts S.R. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009, 77(2):120-123.
33. Lai S.E., Minelly L., O'Keeffe P., et al. Influence of skin color in the development of erlotinib-induced rash: a report from the SERIES clinic. J Clin Oncol 2007, 25(18S). Abstr. 9127.
34. Lurje G., Nagashima F., Zhang W., et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res 2008, 14(23):7884-7895.
35. Wacker B., Nagrani T., Weinberg J., Witt K., Clark G., Cagnoni P.J. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007, 13(13):3913-3921.
36. Wheatley-Price P., Ding K., Seymour L., Clark G.M., Shepherd F.A. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the national cancer institute of Canada clinical trials group study BR.21. J Clin Oncol 2008, 26(14):2350-2357.
37. Klinghammer K., Knodler M., Schmittel A., Budach V., Keilholz U., Tinhofer I. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2010, 16(1):304-310.
38. Perea S., Oppenheimer D., Amador M., et al. Genotypic bases of EGFR inhibitors pharmacological actions. J Clin Oncol 2004, 22(14s). Abstr. 3005.
39. Vallbohmer D., Zhang W., Gordon M., et al. Molecular determinants of cetuximab efficacy. J Clin Oncol 2005, 23(15):3536-3544.
40. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26(10):1626-1634.
41. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359(11):1116-1127.
42. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28(31):4697-4705.
43. Peeters M., Price T.J., Cervantes A., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28(31):4706-4713.
44. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11(1):21-28.
45. Giro C., Berger B., Bolke E., et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 2009, 90(2):166-171.
46. Folprecht G., Gruenberger T., Bechstein W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010, 11(1):38-47.
47. Karthaus M., Hofheinz R., Mineur H., et al. Epidermal growth factor receptor (EGFR) inhibitor-related skin toxicity: review of primary analysis data from a phase II study (20060314) of panitumumab (pmab) with FOLFIRI in the first-line treatment of metastatic colorectal cancer (mCRC). ASCO Gastrointest Cancers Symp 2009, 27(15s). Abstr. e20634.
48. Hecht J.R., Mitchell E., Chidiac T., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27(5):672-680.
49. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360(6):563-572.
50. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11(6):521-529.
51. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26):2733-2743.
52. Johnston S., Pippen J., Pivot X., et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27(33):5538-5546.
53. Lee D.H., Park K., Kim J.H., et al. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010, 16(4):1307-1314.
54. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
55. Lacouture M.E., Mitchell E.P., Piperdi B., et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28(8):1351-1357.
56. Molinari E., de Quatrebarbes J., Andre T., Aractingi S. Cetuximab-induced acne. Dermatology 2005, 211(4):330-333.
57. Scope A., Agero A.L., Dusza S.W., et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007, 25(34):5390-5396.
58. Dreno B., Bettoli V., Ochsendorf F., Layton A., Mobacken H., Degreef H. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol 2004, 14(6):391-399.
59. Yan L., Hsu K., Beckman R.A. Antibody-based therapy for solid tumors. Cancer J 2008, 14(3):178-183.
60. Liu X.Y., Pop L.M., Vitetta E.S. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008, 222:9-27.
61. Schneider-Merck T., Lammerts van Bueren J.J., Berger S., et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010, 184(1):512-520.
62. Bibeau F., Lopez-Crapez E., Di Fiore F., et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009, 27(7):1122-1129.
63. Pander J., Gelderblom H., Antonini N.F., et al. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer 2010, 46(10):1829-1834.
64. Zhang W., Gordon M., Schultheis A.M., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007, 25(24):3712-3718.
65. Clynes R.A., Towers T.L., Presta L.G., Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6(4):443-446.
66. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359(17):1757-1765.
67. Jatoi A., Rowland K., Sloan J.A., et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North central cancer treatment group (N03CB). Cancer 2008, 113(4):847-853.
68. Jatoi A., Thrower A., Sloan J.A., et al. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 2010, 15(9):1016-1022.
69. Scope A., Lieb J.A., Dusza S.W., et al. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 2009, 61(4):614-620.
70. Wong S., Osann K., Lindgren A., Byun T., Mummaneni M. Pilot cross-over study to evaluate regenecare topical gel in patients with epidermal growth factor receptor (HER1/EGFR) inhibitors-induced skin toxicity: the final analysis. J Clin Oncol 2008, 26(15s). Abstr. 20507.
71. Katzer K., Tietze J., Klein E., Heinemann V., Ruzicka T., Wollenberg A. Topical therapy with nadifloxacin cream and prednicarbate cream improves acneiform eruptions caused by the EGFR-inhibitor cetuximab - a report of 29 patients. Eur J Dermatol 2010, 20(1):82-84.
72. Ocvirk J., Rebersek M. Treatment of cetuximab-associated cutaneous side effects using topical aplication of vitamin K1 cream. J Clin Oncol 2009, 27(15s). Abstr. e15087.
73. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27(5):663-671.
74. Kanazawa S., Yamaguchi K., Kinoshita Y., Muramatsu M., Komiyama Y., Nomura S. Aspirin reduces adverse effects of gefitinib. Anticancer Drugs 2006, 17(4):423-427.
75. Kim E.S., Hirsh V., Mok T., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372(9652):1809-1818.
76. Tejpar S., Peeters M., Humblet Y., et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. J Clin Oncol 2007, 25(18s). Abstr. 4037.
77. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21(12):2237-2246.
78. Saltz L.B., Meropol N.J., Loehrer P.J., Needle M.N., Kopit J., Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22(7):1201-1208.
79. Lynch T.J., Patel T., Dreisbach L., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28(6):911-917.
80. Philip P.A., Benedetti J., Corless C.L., et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010, 28(22):3605-3610.